OrthoPediatrics Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw 13% revenue growth, margin stability, and strong international and OPSB expansion. Guidance was raised for 2026, with new product launches and regulatory wins expected to drive further growth and profitability improvements.
-
Clinic expansion is ahead of schedule, with strong revenue and cash flow improvements. New enabling technologies and a robust product pipeline are driving growth, while international and digital initiatives are expanding. Financial outlook remains stable with improved margins and cash flow.
-
A robust new product cycle is underway, with multiple launches in surgical, bracing, and enabling tech platforms planned through 2028. Financial performance is improving, driven by EBITDA growth, efficient set deployment, and specialty bracing expansion, while reduced competition from larger players creates new opportunities.
-
Strong Q4 results included the first quarter of positive free cash flow and robust EBITDA growth. 2026 guidance targets 11%-13% revenue growth, $25M adjusted EBITDA, and break-even cash flow, driven by new product launches, international expansion, and a unique pediatric focus that limits competition.
Fiscal Year 2025
-
Q4 2025 saw 17% revenue growth, record free cash flow, and strong gross margins, driven by innovation and international expansion. 2026 guidance projects 11%-13% revenue growth, $25M Adjusted EBITDA, and breakeven FCF, with a robust product pipeline and new market entries.
-
Guidance was reset to focus on predictable, high-margin growth, excluding volatile 7D and Latin America set sales. New product launches and international expansion are expected to drive growth from 2026, with a strong scoliosis and OPSB portfolio and significant EBITDA improvement anticipated.
-
A pediatric orthopedics-focused company is expanding its global reach and product portfolio through innovation, acquisitions, and education, targeting $233.5M-$234.5M revenue and $15M-$17M EBITDA in 2025. Specialty bracing and enabling technology drive growth, with free cash flow break-even expected in 2026.
-
Trauma Deformity and OPSB divisions are driving strong growth, with new product launches and clinic expansion ahead of plan. Financial guidance has been rebased to a 12% baseline growth, focusing on profitability and cash flow, while a robust innovation pipeline and favorable market dynamics support long-term expansion.
-
Q3 2025 saw 12% revenue growth, strong core segment performance, and a 56% rise in adjusted EBITDA. Profitability and cash flow improved despite headwinds from 7D and LATSAM, with full-year guidance reaffirmed and positive free cash flow targeted for Q4.
-
Revenue guidance for 2025 was reduced due to delays in 7D capital sales and LATAM headwinds, with long-term growth now projected at 12%+ annually. Core segments remain strong, and free cash flow break-even is targeted for 2026, with improved working capital supporting profitability.
-
Exclusive focus on pediatric orthopedics has driven robust growth, with record Q2 revenue and expanding global reach. Specialty bracing and innovative products like VertiGlide and ELLY are key growth drivers, while financials project continued margin improvement and cash flow break-even in 2024.
-
Q2 2025 saw record revenue growth of 16% year-over-year, led by strong performance in scoliosis, trauma, and OPSB, with robust U.S. and international demand. Guidance was raised, and the company expects positive free cash flow in Q4 2025 and break-even in 2026.
-
Q1 2025 saw 17% revenue growth, improved profitability, and reduced cash usage, driven by strong U.S. performance, new product launches, and OPSB expansion. Full-year guidance was raised, with positive free cash flow expected in Q4 and continued focus on innovation and market share gains.
-
Pediatric hospitals have adapted to infection spikes, reducing business impact. Specialty bracing and OPSB expansion drive growth, with new products like DF2, 3P plating, and next-gen scoliosis systems fueling innovation. Gross margins are stable at 72–73% with minimal tariff risk.
Fiscal Year 2024
-
Q4 revenue grew 40% year-over-year to $52.7M, with strong U.S. and segment growth, and adjusted EBITDA more than doubled. 2025 guidance calls for 15–18% revenue growth, continued margin strength, and first positive free cash flow in Q4. OPSB and new product launches are key growth drivers.
-
Growth is driven by PNP Femur and Tibia systems, with new plating and spine products set to launch in 2025–2026. Specialty bracing expansion and the Boston O&P acquisition are fueling revenue growth, while profitability is improving through operational leverage.
-
Stock weakness was linked to technical fund liquidation, not business performance, as core products like scoliosis and 7D navigation saw robust growth and share gains. Financial targets call for 15–19% annual sales growth, with expanding OPSB clinics and a strong innovation pipeline supporting future momentum.
-
Q3 2024 saw record revenue of $54.6M (+37% YoY), driven by strong growth in all segments and robust product launches. Full-year guidance was raised to $202–$204M, with continued margin strength and a focus on cash flow breakeven by 2026.
-
Plans call for high-teens revenue growth, expanding specialty bracing clinics, and launching digital health and enabling technologies, while maintaining strong margins and targeting cash flow positivity by 2026. Product innovation and international expansion are key growth drivers.
-
Q2 2024 revenue grew 33% year-over-year to $52.8M, driven by strong Trauma & Deformity, Scoliosis, and OPSB growth, with Boston O&P integration fueling expansion. Guidance for 2024 is reaffirmed, with adjusted EBITDA expected at $8–$9M and cash flow breakeven targeted by 2026.
-
The business is evolving into a comprehensive pediatric orthopedics provider, with specialty bracing and clinic expansion driving growth. New product launches in scoliosis and strong performance in bracing and Pega segments support a 20% growth aspiration, while investments remain manageable.